Roche, Basel, Switzerland, has completed the acquisition of Flatiron Health, New York City, a market leader in oncology-specific electronic health record software as well as in the curation and development of real-world evidence for cancer research.

With its large network of community oncology practices and academic medical centers across the United States, Flatiron Health has created a technology platform designed to learn from the experience of every patient.

Under the terms of the agreement, the transaction value for the acquisition of Flatiron Health was $1.9 billion on a fully diluted basis, subject to certain adjustments. Flatiron Health will continue its operations as a separate legal entity, and its current business model, network of partnerships, and overall objectives will remain. The integrity of segregated patient protected health information will be preserved, as will dedicated sales and marketing, provider-facing, and life science business activities.

The acquisition aims to enable both companies to accelerate progress toward data-driven personalized healthcare in cancer.